Keyword | CPC | PCC | Volume | Score | Length of keyword |
---|---|---|---|---|---|
ipilimumab nivolumab checkpoint inhibitors | 0.07 | 0.2 | 162 | 65 | 42 |
ipilimumab | 0.47 | 0.4 | 2572 | 92 | 10 |
nivolumab | 0.58 | 0.7 | 3684 | 56 | 9 |
checkpoint | 0.76 | 0.1 | 3675 | 31 | 10 |
inhibitors | 1.79 | 0.8 | 8081 | 25 | 10 |
Keyword | CPC | PCC | Volume | Score |
---|---|---|---|---|
ipilimumab nivolumab checkpoint inhibitors | 1.16 | 0.3 | 5795 | 83 |
is ipilimumab a checkpoint inhibitor | 0.57 | 0.1 | 1189 | 5 |
nivolumab immune checkpoint inhibitor | 1.7 | 0.5 | 1746 | 73 |
is nivolumab a checkpoint inhibitor | 0.99 | 0.2 | 3639 | 94 |
nivolumab is an class of checkpoint inhibitor | 1.04 | 0.6 | 2918 | 95 |
ipilimumab + nivolumab | 1.56 | 0.7 | 8247 | 73 |
ipilimumab and nivolumab patient information | 0.11 | 0.4 | 2422 | 42 |
ipilimumab and nivolumab immunotherapy | 1.57 | 0.9 | 1110 | 2 |
ipilimumab and nivolumab drug class | 1.13 | 0.9 | 220 | 63 |
ipilimumab and nivolumab protocol | 0.4 | 0.5 | 8218 | 63 |
nivolumab and ipilimumab therapy | 0.56 | 0.6 | 9553 | 84 |
nivolumab combined with ipilimumab | 0.95 | 0.1 | 1050 | 5 |
ipilimumab nivolumab combination fda approval | 0.04 | 0.4 | 5216 | 21 |
nivolumab ipilimumab nsclc fda | 1.87 | 0.5 | 5144 | 5 |
ipilimumab and nivolumab mechanism of action | 1.22 | 0.5 | 3025 | 29 |